The Experts below are selected from a list of 234003 Experts worldwide ranked by ideXlab platform
Kinam Park - One of the best experts on this subject based on the ideXlab platform.
-
Drug Delivery of the future chasing the invisible gorilla
Journal of Controlled Release, 2016Co-Authors: Kinam ParkAbstract:For more than 60years Drug Delivery systems have produced numerous controlled release formulations helping patients improve compliance and maximize the Drug efficacy. Development of new controlled Drug Delivery systems was very productive during the period 1950-1980. The productivity, as measured by the number of clinically used formulations, dropped significantly during 1980-2010. This reduced productivity needs to be understood so that the future development of Drug Delivery systems can be accelerated and prolific again. This requires critical evaluation of the current Drug Delivery field, so that the factors inhibiting rapid progress can be identified and resolved. The current Drug Delivery field is faced with an invisible gorilla syndrome, i.e., seeing a gorilla when it is not present and missing a gorilla when it actually exists. Overcoming this syndrome requires a new way of thinking, questioning the status quo. Advances in Drug Delivery technologies occur by an evolutionary process, and thus, the more trials and errors lead to faster advances. The Drug Delivery area needs to nurture the environment where vastly different ideas can be tested, and all data, positive or negative, need to be exchanged freely as they have equal importance.
-
controlled Drug Delivery systems past forward and future back
Journal of Controlled Release, 2014Co-Authors: Kinam ParkAbstract:Controlled Drug Delivery technology has progressed over the last six decades. This progression began in 1952 with the introduction of the first sustained release formulation. The 1st generation of Drug Delivery (1950-1980) focused on developing oral and transdermal sustained release systems and establishing controlled Drug release mechanisms. The 2nd generation (1980-2010) was dedicated to the development of zero-order release systems, self-regulated Drug Delivery systems, long-term depot formulations, and nanotechnology-based Delivery systems. The latter part of the 2nd generation was largely focused on studying nanoparticle formulations. The Journal of Controlled Release (JCR) has played a pivotal role in the 2nd generation of Drug Delivery technologies, and it will continue playing a leading role in the next generation. The best path towards a productive 3rd generation of Drug Delivery technology requires an honest, open dialog without any preconceived ideas of the past. The Drug Delivery field needs to take a bold approach to designing future Drug Delivery formulations primarily based on today's necessities, to produce the necessary innovations. The JCR provides a forum for sharing the new ideas that will shape the 3rd generation of Drug Delivery technology.
-
oral controlled release formulation design and Drug Delivery
2014Co-Authors: Hong Wen, Kinam ParkAbstract:Oral controlled release formulation design and Drug Delivery : , Oral controlled release formulation design and Drug Delivery : , کتابخانه الکترونیک و دیجیتال - آذرسا
-
facing the truth about nanotechnology in Drug Delivery
ACS Nano, 2013Co-Authors: Kinam ParkAbstract:Nanotechnology in Drug Delivery has been manifested into nanoparticles that can have unique properties both in vitro and in vivo, especially in targeted Drug Delivery to tumors. Numerous nanoparticle formulations have been designed and tested to great effect in small animal models, but the translation of the small animal results to clinical success has been limited. Successful translation requires revisiting the meaning of nanotechnology in Drug Delivery, understanding the limitations of nanoparticles, identifying the misconceptions pervasive in the field, and facing inconvenient truths. Nanoparticle approaches can have real impact in improving Drug Delivery by focusing on the problems at hand, such as enhancing their Drug loading capacity, affinity to target cells, and spatiotemporal control of Drug release.
-
Targeted Drug Delivery to tumors: Myths, reality and possibility
Journal of Controlled Release, 2011Co-Authors: You Han Bae, Kinam ParkAbstract:The ultimate goal of Drug Delivery research is to help patients by developing clinically useful formulations. During the last several decades controlled Drug Delivery technology has advanced significantly, leading to the development of various clinical formulations improving patient compliance and convenience [1]. Current technologies allow Delivery of Drugs at desired release kinetics for extended periods of time ranging from days to years. Oral and transdermal Drug Delivery systems routinely deliver Drugs for 24 h, substantially improving Drug efficacy and minimizing side effects. Implantable systems can locally deliver Drugs for months, even years. While significant advances have been made, there are still areas where substantial improvements need to be made to reach the next level of clinical relevance. One such area is targeted Drug Delivery to solid tumors. The clinically significant impact of targeted Drug Delivery lies in the ability to specifically target a Drug or Drug carrier to minimize Drug-originated systemic toxic effects. Successful translation (from bench to bedside) of potential cancer and gene therapies, particularly small interfering RNA (siRNA) Delivery, will largely depend on targeted Drug Delivery strategies. Overcoming the many challenges of identifying a successful targeted Drug Delivery strategy requires an understanding of events involving transport of Drug or Drug carrier to a target site after intravenous (i.v.) administration as well as issues relevant for specific target diseases and the body’s response toward a Drug Delivery system. The current lack of clear recognition of problems facing the Drug Delivery field can be anticipated to result in only marginal advances in targeted Drug Delivery technologies in the coming years. The current unmet needs and challenges in this area were summarized by Professor Alexander T. Florence who is one of the few who raised awareness on the exaggerated claims of the nanoparticle-based Drug targeting [2,3]. They need to be better appreciated and understood for achieving greater success in Drug targeting to tumors. Thus, it would be profitable to address a variety of issues and factors that could affect the development of improved targeted Drug Delivery systems. Many terms have been used to describe nano-sized Drug Delivery systems, and here the term “nanoparticle” is used to represent a spectrum of systems, including nanocarrier, nanovehicle, nanosystem, nanostructure, and other terms used in the literature.
Michael J. Rathbone - One of the best experts on this subject based on the ideXlab platform.
-
fundamentals and applications of controlled release Drug Delivery
2012Co-Authors: Jürgen Siepmann, Ronald A Siegel, Michael J. RathboneAbstract:The Need for Drugs and Drug Delivery Systems.- Overview of Controlled Release Mechanisms.- Hydrophobic Polymers of Pharmaceutical Significance.- Hydrogels.- Biodegradable Polymers in Drug Delivery Systems.- Diffusion Controlled Drug Delivery Systems.- Swelling Controlled Drug Delivery Systems.- Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery Systems.- Porous Systems.- Targeted Delivery Using Biodegradable polymeric Nanoparticles.- Liposomes in Drug Delivery.- Receptor Mediated Delivery Systems for Cancer Therapeutics.- Biological Rhythms, Drug Delivery, and Chronotherapeutics.- Site Specific Controlled Release for Cardiovascular Disease - Translational Direction.- Drug Delivery Systems to Fight Cancer.- Applications of Vaccine Delivery in Infectious Diseases.- Tissue Engineering in Drug Delivery.- The Shaping of Controlled Release Drug Product Development by Emerging Trends in the Commercial, Regulatory and Political Macro-Environment
-
modified release Drug Delivery technology
2007Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S RobertsAbstract:Modified-release Drug Delivery technology , Modified-release Drug Delivery technology , کتابخانه مرکزی دانشگاه علوم پزشکی تهران
-
modified release Drug Delivery technology
(2 vols). (2nd ed. ed.). Informa Healthcare: USA. (2008), 2002Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S RobertsAbstract:Oral modified-release Delivery systems TIMERx oral controlled-release Drug Delivery system MASRx and COSRx sustained-release technology Procise - Drug Delivery systems based on geometric configuration ringcap technology Smartrix system - design characteristics and release properties of a novel erosion-controlled oral Delivery system Theriform technology Accudep technology for oral modified Drug release osmotically controlled tablets three-phase pharmaceutical form - THREEFORM - with controlled release of amorphous active ingredient for once-daily administration.
Michael S Roberts - One of the best experts on this subject based on the ideXlab platform.
-
modified release Drug Delivery technology
2007Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S RobertsAbstract:Modified-release Drug Delivery technology , Modified-release Drug Delivery technology , کتابخانه مرکزی دانشگاه علوم پزشکی تهران
-
modified release Drug Delivery technology
(2 vols). (2nd ed. ed.). Informa Healthcare: USA. (2008), 2002Co-Authors: Michael J. Rathbone, Jonathan Hadgraft, Michael S RobertsAbstract:Oral modified-release Delivery systems TIMERx oral controlled-release Drug Delivery system MASRx and COSRx sustained-release technology Procise - Drug Delivery systems based on geometric configuration ringcap technology Smartrix system - design characteristics and release properties of a novel erosion-controlled oral Delivery system Theriform technology Accudep technology for oral modified Drug release osmotically controlled tablets three-phase pharmaceutical form - THREEFORM - with controlled release of amorphous active ingredient for once-daily administration.
Anuj Chauhan - One of the best experts on this subject based on the ideXlab platform.
-
ophthalmic Drug Delivery through contact lenses
Investigative Ophthalmology & Visual Science, 2004Co-Authors: Derya Gulsen, Anuj ChauhanAbstract:PURPOSE. Currently available ophthalmic Drug Delivery systems are inefficient and may lead to side effects. To increase efficiency and reduce side effects, the authors propose disposable particle-laden soft contact lenses for ophthalmic Drug Delivery. METHODS. The essential idea is to encapsulate the ophthalmic Drug formulations in nanoparticles and to disperse these Drug-laden particles in the lens material, such as poly-2-hydroxyethyl methacrylate (p-HEMA) hydrogels. The Drug-laden p-HEMA hydrogels were synthesized by free radical solution polymerization of the monomers in presence of nanoparticles. The particle-laden hydrogels were characterized by light-transmission and electron microscopy studies. Release profiles of lidocaine, a model hydrophobic Drug, were measured by UV-Vis spectrophotometry. RESULTS. Microemulsions of hexadecane in water stabilized with a silica shell around the particles produced transparent hydrogels. Contact lenses made with particle-laden hydrogels released therapeutic levels of Drug for a few days. CONCLUSIONS. Particle-laden hydrogels are promising candidates for ophthalmic Drug Delivery. They are transparent and can release Drugs for extended periods. The Drug Delivery rates can be controlled by varying the loading of nanoparticles in the gel.
Robert Langer - One of the best experts on this subject based on the ideXlab platform.
-
wireless on demand Drug Delivery
Nature Electronics, 2021Co-Authors: Seyed M Mirvakili, Robert LangerAbstract:Wireless on-demand Drug Delivery systems exploit exogenous stimuli—acoustic waves, electric fields, magnetic fields and electromagnetic radiation—to trigger Drug carriers. The approach allows Drugs to be delivered with controlled release profiles and minimal off-target effects. Recent advances in electronics and materials engineering have led to the development of sophisticated systems designed for specific applications. Here we review the development of wireless on-demand Drug Delivery systems. We examine the working mechanisms, applications, advantages and limitations of systems that are triggered by electric fields, magnetic fields or electromagnetic radiation. We also provide design guidelines for the development of such systems, including key metrics for evaluating the practicality of different smart Drug Delivery systems. This Review examines wireless on-demand Drug Delivery systems that are triggered by electric fields, magnetic fields or electromagnetic radiation, and provides design guidelines for the development of such systems.
-
Drug Delivery by supramolecular design
Chemical Society Reviews, 2017Co-Authors: Matthew J Webber, Robert LangerAbstract:The rational design of Drug Delivery approaches leveraging supramolecular chemistry (i.e., “chemistry beyond the molecule”) has garnered significant interest in recent years toward improving therapeutics. By using specific, dynamic, and tunable non-covalent interactions, engineered approaches to Drug Delivery can be realized. Certain benefits to this approach are molecular-level control of composition, improved routes for incorporating and targeting Drugs, and new strategies to create Delivery devices that respond to a variety of physiologic indicators. Some of the most recognizable supramolecular motifs – macrocyclic host–guest complexes – afford logical application to Drug Delivery in using Drug as guest. The use of supramolecular motifs may further give rise to materials for the controlled encapsulation and release of therapeutics. Furthermore, given the majority of supramolecular motifs in water are directed by hydrophobic interactions, cooperative Delivery strategies can be realized. The modularity of supramolecular interactions also facilitates opportunities to combine multiple Drugs within one Delivery platform, as well as the facile incorporation of targeting units. In sum, supramolecular design offers ample opportunity to improve the precision of pharmaceutical practice. In the context of clinical translation, features of supramolecular design may prove additionally advantageous, specifically in enabling quantitative Drug loading, molecularly discrete Delivery devices, and a priori knowledge of carrier degradation and clearance mechanisms. As such, the design opportunities afforded by supramolecular chemistry will play a vital role in the future of the Drug Delivery field.
-
emerging frontiers in Drug Delivery
ChemInform, 2016Co-Authors: Mark W Tibbitt, James E Dahlman, Robert LangerAbstract:Medicine relies on the use of pharmacologically active agents (Drugs) to manage and treat disease. However, Drugs are not inherently effective; the benefit of a Drug is directly related to the manner by which it is administered or delivered. Drug Delivery can affect Drug pharmacokinetics, absorption, distribution, metabolism, duration of therapeutic effect, excretion, and toxicity. As new therapeutics (e.g., biologics) are being developed, there is an accompanying need for improved chemistries and materials to deliver them to the target site in the body, at a therapeutic concentration, and for the required period of time. In this Perspective, we provide an historical overview of Drug Delivery and controlled release followed by highlights of four emerging areas in the field of Drug Delivery: systemic RNA Delivery, Drug Delivery for localized therapy, oral Drug Delivery systems, and biologic Drug Delivery systems. In each case, we present the barriers to effective Drug Delivery as well as chemical and mater...
-
microchip technology in Drug Delivery
Annals of Medicine, 2000Co-Authors: John T Santini, Amy C Richards, Rebecca Scheidt, Michael J Cima, Robert LangerAbstract:The realization that the therapeutic efficacy of certain Drugs can be affected dramatically by the way in which they are delivered has created immense interest in controlled Drug Delivery systems. Much previous work in Drug Delivery focused on achieving sustained Drug release rates over time, while a more recent trend is to make devices that allow the release rate to be varied over time. Advances in microfabrication technology have made an entirely new type of Drug Delivery device possible. Proof-of-principle experiments have shown that silicon microchips have the ability to store and release multiple chemicals on demand. Future integration of active control electronics, such as microprocessors, remote control units, or biosensors, could lead to the development of a 'pharmacy on a chip,' ie 'smart' microchip implants or tablets that release Drugs into the body automatically when needed.
-
microchips as controlled Drug Delivery devices
Angewandte Chemie, 2000Co-Authors: John T Santini, Amy C Richards, Rebecca Scheidt, Michael J Cima, Robert LangerAbstract:Controlled-release systems are common in a number of product areas, including foods, cosmetics, pesticides, and paper. Microencapsulated systems, for example, are used for the release of flavors and vitamins in foods, fragrances in perfumes, and inks in carbonless copy paper. Controlled-release systems for Drug Delivery first appeared in the 1960s and 1970s. In the past three decades, the number and variety of controlled release systems for Drug-Delivery applications has increased dramatically. Many of these use polymers having particular physical or chemical characteristics such as biodegradability, biocompatibility, or responsiveness to pH or temperature changes. However, recent advances in the field of microfabrication have created the possibility of a new class of controlled-release systems for Drug Delivery, namely, that of small, programmable devices. Their small size, potential for integration with microelectronics, and ability to store and release chemicals on demand could make controlled-release microchips useful in a number of areas, including medical diagnostics, analytical chemistry, chemical detection, industrial process monitoring and control, combinatorial chemistry, microbiology, and fragrance Delivery. More importantly, Drug-Delivery microchips resulting from this convergence of controlled release and microfabrication technologies may provide new treatment options to clinicians in their fight against disease.
